TP + cetuximab + tislelizumab

TP + cetuximab + tislelizumab is a combination regimen under investigation for the treatment of unresectable locally advanced head and neck squamous cell carcinoma (LA HNSCC). The regimen includes: - **TP chemotherapy:** "TP" refers to a standard chemotherapy combination of **docetaxel** and **cisplatin**. - **Cetuximab:** a chimeric monoclonal antibody targeting the epidermal growth factor receptor (**EGFR**), inhibiting cancer cell proliferation and survival. - **Tislelizumab:** a humanized IgG4 monoclonal antibody targeting programmed death receptor-1 (**PD-1**) on T cells, blocking its interaction with PD-L1 and PD-L2, thereby enhancing immune-mediated antitumor responses. The combination aims to increase the efficacy of standard chemoradiotherapy with the synergistic effects of immune checkpoint inhibition and EGFR blockade[1][5][6].